We can't find the internet
Attempting to reconnect
17003.1 PFLS-LS
Development of stable affinity columns for antibody purification
Zusammenfassung
Development of stable affinity columns for antibody purification
Weitere Texte
Abstract
Monoclonal antibodies (MAbs) account for a large share of the rapidly growing biological drugs|market. Whilst the market for such drugs is expected to reach $62.3 billion in 2015, the biggest|obstacle in MAb production ¿ purification, is still suboptimal. Expensive Protein A resins are|used but they can be sensitive to elution and sterilization conditions. In combination with|ChromaCon¿s proprietary technology, this project aims to develop and commercialize a novel,|efficient and cost effective antibody purification process using a novel affinity reagent for|humanized antibodies.
Beteiligte
Michael Bavand
Wirtschaftspartner
michael.bavand@chromacon.ch
ChromaCon AG Michael Bavand Technoparkstrasse 1 8005 Zürich ZH CH
Jeffrey Bode
Kontaktperson
bode@org.chem.ethz.ch
ETH Zürich Jeffrey Bode Wolfgang-Pauli-Strasse 10 8093 Zürich ZH CH
Projektdetails
- Forschungsstelle
- INNOSUISSE
- Projektstatus
- Abgeschlossen
- Projekttyp
- Forschungsprojekt
- Startdatum
- 2015-01-31
- Enddatum
- 2017-10-31
- Bewilligte Gesamtkosten
- CHF 368184.00
- Sektion
- 20 Förderbereich Life Sciences
- NABS Politikbereich
- Industrielle Produktivität und Technologie
Forschungsdisziplinen
- T490 Biotechnology 100.0%